ArticlesBronchoscopic lung-volume reduction with Exhale airway stents for emphysema (EASE trial): randomised, sham-controlled, multicentre trial
Introduction
Surgery to reduce lung volume in patients with pulmonary emphysema can increase residual volume (RV) and improve breathing mechanics and dyspnoea, even in individuals with homogeneous disease. However, with substantial surgical morbidity, adoption of this procedure has been low.1, 2, 3
Airway bypass is a bronchoscopic procedure to reduce lung volume that is designed for treatment of severe homogeneous emphysema. With this technique, passages are created in the bronchial airways to deflate air trapped in the emphysematous regions, and paclitaxel-eluting stents are placed to maintain passageway patency.4, 5 In preclinical, ex-vivo, and pretransplant studies, airway bypass released trapped air by bronchoscopic creation of transbronchial passageways.5, 6, 7, 8 In a feasibility study,5 efficacy was shown for airway bypass at 6 months in patients with a ratio of RV to total lung capacity (TLC) of more than 67%, a proportion that is also predictive of improvement in forced vital capacity (FVC) after lung-volume reduction surgery.9
The Exhale drug-eluting stent (Broncus Technologies, Mountain View, CA, USA) is composed of stainless steel and silicone and contains paclitaxel, which is intended to inhibit fibrotic responses.7 We designed the Exhale airway stents for emphysema (EASE) trial to investigate safety and efficacy of airway bypass for patients with severe homogeneous emphysema.
Section snippets
Participants
We undertook a multicentre, double-blind, randomised, sham-controlled trial at 38 specialist respiratory centres worldwide. The adaptive study design of the EASE trial and screening process to select patients with severe homogeneous disease has been published previously.10
Panel 1 summarises key inclusion and exclusion criteria. We focused inclusion criteria on definition of a population with severe hyperinflation. All participants had to undergo at least 6 weeks of pulmonary rehabilitation
Results
Between Oct 18, 2006, and April 8, 2009, 1522 people were screened for the study and 319 underwent randomisation. 212 participants were randomly assigned airway bypass (four were allocated after enrolment closed so did not receive the intervention) and 107 were allocated sham control (figure 1). 6-month follow-up data were available for 195 (94%) patients in the airway bypass arm and 90 (84%) who were assigned sham control. Seven (3%) participants in the airway bypass arm and seven (7%) who
Discussion
Findings of the EASE trial showed that at day 1, airway bypass released trapped gas from hyperinflated regions, thereby improving pulmonary function. However, durability was limited by pulmonary function tests and subjective, functional, and post-hoc CT measures. Outcomes for sham control and airway bypass were similar at months 3, 6, and 12. Although the EASE trial failed to show a difference between treatment arms with respect to the 6-month primary efficacy endpoint, invaluable lessons were
References (17)
- et al.
Persistent benefit from lung volume reduction surgery in patients with homogeneous emphysema
Ann Thorac Surg
(2009) - et al.
Airway bypass treatment of severe homogeneous emphysema: taking advantage of collateral ventilation
Thorac Surg Clin
(2009) - et al.
Clinical application of airway bypass with paclitaxel-eluting stents: early results
J Thorac Cardiovasc Surg
(2007) - et al.
Feasibility and safety of airway bypass stent placement and influence of topical mitomycin C on stent patency
J Thorac Cardiovasc Surg
(2005) - et al.
Prolongation of patency of airway bypass stents with use of drug-eluting stents
J Thorac Cardiovasc Surg
(2006) - et al.
Bronchial fenestration improves expiratory flow in emphysematous human lungs
Ann Thorac Surg
(2003) - et al.
CAD in clinical trials: current role and architectural requirements
Comput Med Imaging Graph
(2007) - et al.
“Density mask”: an objective method to quantitate emphysema using computed tomography
Chest
(1988)
Cited by (190)
The minimal important difference of the constant work rate cycle test in severe COPD
2023, Respiratory MedicineCOPD: Providing the right treatment for the right patient at the right time
2023, Respiratory MedicineAdvances in Surgical and Mechanical Management of Chronic Obstructive Pulmonary Disease
2022, Medical Clinics of North AmericaCitation Excerpt :This reduces both static and dynamic hyperinflation. The Safety and Effectiveness of the Exhale® Drug-Eluting Stent in Homogeneous Emphysema Subjects With Severe Hyperinflation (EASE) trial15 evaluated this technique in patients with severe emphysema and hyperinflation. The study was unable to show a difference in FEV1 or dyspnea as reported by the modified Medical Research Council score (mMRC) between the intervention and control groups at 6 and 12 months.
Endoscopic Treatment of Chronic Obstructive Pulmonary Disease
2021, Cohen's Comprehensive Thoracic AnesthesiaInterventional Bronchoscopic Therapies for Chronic Obstructive Pulmonary Disease
2020, Clinics in Chest MedicineCitation Excerpt :Airway bypass is a bronchoscopic technique designed for homogeneous emphysema in which airway passages are created to deflate trapped air using paclitaxel eluding-eluting stents to maintain patency of the bypass tracts (Broncus Technologies, Mountain View, CA). The Exhale Airway Stents for Emphysema (EASE) trial is a randomized, sham-controlled study designed to investigate the safety and efficacy of these stents.21 EASE enrolled 315 patients (208 in the stent arm) with severe homogeneous emphysema that were severely gas trapped.
- †
See end of report for details of the EASE trial study group